Research programme: viral entry inhibitors - Samaritan

Drug Profile

Research programme: viral entry inhibitors - Samaritan

Alternative Names: SP 10; SP 10T1; SP-03; SP-30

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Georgetown University
  • Class Benzamides; Quinuclidines
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hepatitis C; HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
  • 06 Aug 2007 Preclinical data added to the viral infections antimicrobial and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top